Multiple sclerosis (MS) is a chronic, progressive condition that involves cell-mediated autoimmune attack on myelinating cells of the CNS (oligodendrocytes).
🏘 Epidemiology
- It is 3x more common in women.
- Most commonly occurs in young adults (20-40 years).
- More common in northern hemisphere (5x).
Pathophysiology
The function of myelin is to aid electrical impulse transmission. It insulates the axon as such. The myelinating cells of the CNS are the oligodendrocytes, while in the PNS it is the Schwann cell. MS only affects the CNS typically as oligodendrocytes are attacked and not Schwann cells.
What occurs in MS is we get infiltration of auto-reactive lymphocytes across the blood-brain-barrier, entering the CNS. These autoimmune cells then infiltrate the inflamed myelin → damage of the myelin and impaired electrical signalling. It is a form of type 4 hypersensitivity.
Early on we may see re-myelination of the axon and resolution of symptoms. However, later on in the disease progression, symptoms become more permanent as gliosis (the proliferation and hypertrophy of glial cells - mostly astrocytes) impairs this process. Plaques of demyelination and later on axonal loss are the hallmarks of the disease.
⚠️ Risk factors
- HLA-DRB1 implicated.
- EBV and HHV-6 - as seen in infections such as glandular fever and rosela infantum.
- Vitamin D deficiency
- Cigarette smoking
- Obesity in early life
💡 HLA-A*02 is deemed as protective against MS.
🔢 Classification
There are 3 types of MS that we can identify. However, preceding diagnosis of MS we usually see a clinically isolated syndrome (CIS).
- Clinically isolated syndrome - it refers to the first neurological episode lasting at least 24 hours as a result of inflammation or demyelination in the CNS. The episode has no associated fever or infection. If the associated CIS is accompanied by MRI-detected brain lesions then there is a 60-80% chance of a secondary even and MS diagnosis within several years.It can be either:
- Monofocal - a single neurological sign or symptom as a result of a single lesion (e.g. optic neuritis).
- Multifocal - multiple symptoms experienced due to multiple diffuse lesions (e.g. optic neuritis and paraesthesia of the legs).
- Relapsing-remitting MS - it is the most common disease pattern, characterised by disease and neurological symptoms followed by a period of recovery. It can be further classified as:
- Worsening - level of disability is progressing with time.
- Not worsening - disability is not advancing.
- Active - new symptoms and lesions are developing and showing on MRI.
- Inactive - no new symptoms or lesions are developing.
About 80% of MS courses are RRMS at presentation.
- Primary progressive MS - steadily worsening from the onset of symptoms without relapse or remission from the start.
- Secondary progressive MS - it is secondary to an initial course of RRMS, however, now there is progression without remission. It too can be classified the same way as RRMS as active/inactive and worsening/not worsening.
😷 Presentation
Lesions vary in their location, meaning that symptoms also change over time. We can say that lesions are disseminated in time and space.
Symptoms are progressive >24 hours. They usually last days-weeks before improving (depending on the disease course of course).
Some symptoms may include:
- Visual
- ⭐️ Optic neuritis - the most common presentation.
- Ophthalmoplegia
- Intranuclear ophthalmoplegia - occurs due to lesion of the medial longitudinal fasciculus within the brainstem. These fibres ensure that the eyes move together by coordinating the movements. It will present as a conjugate lateral gaze palsy. This means we have an inability of the eye to adduct. For example, when there is a left intranuclear ophthalmoplegia, the left eye can abduct and look left, but when looking right (addicting), it will remain in the middle.
- Optic atrophy
- Uhthoff’s phenomenon - worsening of vision when the body temperature rises.
- Sensory
- ⭐️ Paraesthesia
- Numbness
- Trigeminal neuralgia - pain on one side of the face.
- Lhermitte’s syndrome - paraesthesia in the limbs when flexing the neck, it indicates dorsal column pathology within the cervical spine.
- Motor
- ⭐️ Spastic weakness - commonly seen in the legs. MS is a disease of the CNS and so an UMN lesion is seen. LMN signs are not indicative of MS.
- Bell’s palsy
- Horners syndrome
- ⭐️ Incontinence
- Cerebellar
- Ataxia
- Charcot’s neurological triad
- Scanning speech (ataxic dysarthria)
- Nystagmus
- Intention tremors
🔍 Investigations
⭐️ Once again, we need to see lesions disseminated in time and space.
MRI - we may see demyelinating features such as:
- High signal T2 lesions (seen as very bright white lesions [hyperintense] against the greyer surrounding brain tissue) that are ovoid in shape.
- Periventricular plaques - T2-hyperintertense lesions in direct contact with the lateral ventricles.
- Dawson fingers - periventricular demyelinating plaques distributed along the endulzar veins, perpendicular to the lateral ventricles. Specific for MS.
- FBC and vitamin B12
- TFTs
- Lumbar puncture - may show oligoclonal bands. These are bands of immunoglobulins in the CSF. They indicate inflammation within the CNS. Sensitive to MS, but also found in Lyme disease and SLE.
The McDonald criteria is the generally accepted criteria for MS:
🧰 Management
We will discuss the general management of acute relapse and symptomatic treatments and then we will discuss the options for immunomodulation in specific types of MS:
Acute relapse:
- 🥇 High-dose steroids
- Methylprednisolone - 1g IV is standard, but oral is not considered inferior. It is given for 3 days or 5 days if severe-relapse
- 🥈 Plasmapheresis
- Symptomatic management
- Physiotherapy
- Spastic paralysis - botox or baclofen
- Fatigue - exercise therapy or modafinil
- Incontinence - oxybutynin
- Depression - SSRIs
- Erectile dysfunction - sildenafil
- Tremor - clonazepam
- Oscillopsia- gabapentin
RRMS:
- Injectables
- Interferon-beta
- Glatiramer acetate - a disease modifying drug, MOA not fully understood, but it is thought that it binds to MHC Class II on MBP-specific antigen-presenting cells, preventing MBP from stimulating these cells.
- Oral agents
- Teriflunomide - inhibits the proliferation of rapidly dividing T and B cells. It works by inhibiting the mitochondrial enzyme dihydro-orotate dehydrogenase.
- Dimethyl fumarate
- Monoclonal antibodies
- Ofatumumab
- Natalizumab - a4-B1 integran antagonist found on leukocyte surface.
- Alemtuzumab
- Ocrelizumab
CIS:
- Interferon-beta
- Glatiramer acetate
- Teriflunomide
PPMS:
- Ocrelizumab
SPMS:
All disease modifying therapies can be used in active SPMS.